How to Report Pharmaceutical Fraud: The Records That Show Where the Money Went

To work out how to report pharmaceutical fraud, speak with our whistleblower experts about the drug, the records and the government healthcare payment involved. You may know why a speaker was paid for an event that never happened, why a pharmacy pushed another refill or why a hospital discount disappeared from a rebate calculation. Your account can explain the decision behind the paperwork.

A pharmaceutical whistleblower can bring a qui tam case on the government’s behalf. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We assess the conduct and the evidence with you, then bring in pharmaceutical whistleblower lawyers with the experience your case needs.

What Proof Do You Need as a Whistleblower?

Useful proof connects what the company did, who directed it and how it affected a government payment or rebate. We begin with what you personally know and the records you already have. You can also tell us where other records sit and which colleagues understand them. You do not need a complete file to start the conversation.

Questions about patient information, confidentiality or privileged material belong in that conversation with us and your whistleblower counsel.

The same prescription can involve a manufacturer, wholesaler, pharmacy, benefit manager and health plan. The drug travels through distribution. Rebates and service payments follow their own agreements. Someone in sales may know the instruction that started the transaction, while someone in finance knows how the resulting payment was classified. We help connect what you saw in your department to how the government was billed.

The Records Behind the Pharmaceutical Fraud

The useful records depend on the conduct. A presentation, a referral spreadsheet and a price calculation answer different questions, but each can connect an internal decision to money paid by Medicare or owed to Medicaid. Taxpayers lose the rebate Medicaid was owed, and patients can receive refill calls shaped by sales targets.

Promotion, Medical Affairs and Clinical Claims

Promotional decks, approved labeling, training materials and study results show what the company knew and what it told prescribers. For off-label promotion connected to false claims, we examine the promoted use alongside the coverage representation and the resulting government-paid prescriptions.

The whistleblower’s complaint against Abbott Laboratories alleged that representatives had to record their physician visits but were instructed to leave off-label discussions out of the call notes. It also alleged that sales scripts omitted risks described in the product insert. The approved document, the training script and the employee’s account can therefore tell different parts of the same sales call.

Clinical-trial and safety concerns bring study protocols, results and submission versions into that comparison. A medical-affairs employee may know which findings reached the promotional team and how the scientific claim changed before it reached a doctor or payer.

Speaker Programs, Consulting and Research Payments

Speaker contracts and honoraria show who was paid. Invitations, attendance records, presentations and receipts show what the payment supposedly bought. Prescriber-selection criteria can explain why that doctor received the invitation.

Novartis admitted paying doctors for events that never took place. It also admitted that a sales representative arranged fake restaurant receipts and used the money to buy gift cards for high-prescribing doctors. The receipt made a dinner appear to exist. The employee who knew where the money went could explain the fiction behind it.

For speaker program kickbacks, the connection runs from selection through payment to prescribing. For consulting, advisory boards and purported research, we examine the agreement, the need for the work, what was actually delivered and who in sales helped arrange it. A survey or data-purchase contract needs to be understood alongside the work and the prescribing business it generated.

Specialty-Pharmacy Referrals and Refill Calls

Refill scorecards, referral-allocation terms and counseling scripts can show how a manufacturer’s commercial targets reached a pharmacy’s patient calls. In the Exjade case, Accredo admitted that the scorecards measured continued refills without excluding patients who stopped because of side effects or a physician’s instruction. The pharmacy’s position on the scorecard helped determine how much new referral business it received.

The government’s complaint described the pressure on another pharmacy in the same network:

That is why the next patient referral can matter as much as a check. Pharmacy staff may understand both the refill target and what callers were told to say to reach it.

Copay Donations and Application Timing

Donation approvals, waiting lists, fund-opening messages and application timestamps can connect a manufacturer’s money to assistance for its own drug. Advanced Care Scripts acknowledged relaying foundation data to Teva so the manufacturer could compare its donations with spending on Copaxone patients. When a fund reopened, the pharmacy promptly sent an application batch consisting almost entirely of those patients.

For copay application batch files, timing is part of the evidence. The donation, notice of reopening, application submission and approval tell the story together. Where the concern is a fund designed around one product, eligibility definitions and communications about changing them show which patients the fund was built to serve.

Free Products and Testing

Sample inventories, delivery records and paid claims connect a free product to what a practice billed. Reimbursement assurances add another set of records: the purchase terms, denied claim and manufacturer’s payment to cover it. In EyePoint’s DEXYCU case, the government alleged an assurance program that compensated surgical centers when insurance denied payment or paid less than their purchase cost, alongside excessive free samples.

Free testing records can connect a diagnostic program to a manufacturer’s sales calls. QOL Medical acknowledged receiving results from breath tests it funded and passing information to its sales force for Sucraid calls. It tracked whether representatives converted positive tests into prescriptions. Test-program materials, data transfers and sales follow-up explain how a diagnostic service became a source of customers.

Manufacturer-Run Prior Authorization

For manufacturer-run prior authorization, the original medical information belongs beside the submitted form, call script and approval. A whistleblower’s complaint against Shire alleged that sales representatives submitted requests while impersonating qualified professionals or office staff. The person who knows who prepared the request may explain a claim that looks routine to the payer.

Prices, Rebates and the Reported Number

Pricing evidence connects the contract and actual payment to the calculation sent to the government. The key records are agreements and side terms, invoices, credits, rebate receipts, calculation versions and the final report. The reporting period identifies which transactions went into which number.

Wyeth and Pfizer agreed to a $784.6 million settlement over alleged bundled Protonix discounts omitted from Medicaid Best Price. The government alleged that Wyeth used discounts on oral and intravenous Protonix to win hospital business. Patients discharged on the oral drug were likely to keep taking it, with Medicaid among the payers afterward. The hospital contract bought access to that later business. The allegedly concealed discount also reduced the rebates Medicaid received.

The same service-fee label can appear at another point in the payment chain. In the Elixir case, the Justice Department alleged that retained manufacturer rebates were reported as service fees even though manufacturers had not negotiated those fees. For Part D rebate reporting, the comparison is between what the manufacturer paid, what services it agreed to buy and what the plan reported for Medicare’s payment reconciliation.

Average Manufacturer Price and Average Sales Price workpapers show which payments and concessions reached the reported number. For Average Wholesale Price, we compare the supplier’s actual price with the reimbursement benchmark.

Medicaid drug-category and base-date records, and VA Federal Ceiling Price calculations, show which pricing treatment the company used.

The public list price is only one part of this story. In The Association Between Drug Rebates and List Prices, published in 2020, the USC Schaeffer Center found that increases in estimated rebates were associated with increases in list prices. Its estimate of the gap between list and net prices included discounts and payments to wholesalers and pharmacies as well as PBM rebates. An insider’s agreements and ledgers can identify the actual payments behind that gap. We examine who received each payment and how it reached the government report.

Manufacturing and Quality

Manufacturing records connect an internal quality finding to the batch released and what the company told regulators. In the Cidra whistleblower complaint, GlaxoSmithKline allegedly blamed drug mix-ups on events outside its control despite internal findings at the plant. The useful comparison is the internal investigation, the release decision and the report sent outside the company, tied to the affected product and government-paid claims.

Discounted Purchases and Pricing Agreements

For 340B concerns, the relevant records identify the drug units, covered entity, patient eligibility, Medicaid rebate treatment and ceiling price. Those connections distinguish diversion, duplicate discounts and manufacturer overcharging.

A contracting employee concerned about coordination between competing manufacturers may know the bids, customer-allocation communications and contacts behind the agreed price or supply. We assess those arrangements alongside the resulting sales and payments from government health care programs.

The Dates That Explain a Decision

A useful chronology connects an instruction to what happened afterward. We look at when a program began, who changed its terms, what concerns reached decision makers and what happened to the next payment, prescription or report. The versions on either side of a change can be more revealing than the final policy alone.

Accredo’s admissions in the Exjade settlement show why. After the January 2010 boxed warning, its revised call protocols still omitted the more severe adverse reactions described in that warning. When Novartis ended the extra-referral incentive in April 2012, Accredo stopped assigning nurses to those therapy calls that month. The counseling changed with the business arrangement. An employee who knows which script was used, and when, can connect those decisions.

From Your Account to a Pharmaceutical Whistleblower Case

We assess the payment connection, test the account against the documents and develop the case with pharmaceutical whistleblower counsel. Sales, medical affairs, pricing and pharmacy staff each see a different part of the transaction. Our work is to connect those parts and identify the experience the case needs.

Biogen’s $900 million settlement shows what a whistleblower’s case can accomplish. After the government declined to join, a former employee pursued the case alleging that speaker and consulting payments induced prescriptions. The Justice Department announced the civil settlement in September 2022. We work through the government’s decision whether to join with you.

We also assess the recovery and the whistleblower’s share as separate amounts. If you have already reported the conduct, have concerns about anonymity or retaliation, or handled the transaction yourself, bring those questions to us. They belong in the discussion about your case.

The Decision You Saw Inside

If you know who changed the calculation, paid for the supposed service or tied referrals to refills, talk with our whistleblower experts about your pharmaceutical fraud case. We develop the strategy with you, bring in pharmaceutical whistleblower lawyers who understand the conduct and stay beside you through the pursuit of the case and your reward.